Clovis Oncology Inc. (NASDAQ:CLVS) shares were down 4.4% during mid-day trading on Wednesday . The company traded as low as $13.92 and last traded at $14.07, with a volume of 250,284 shares trading hands. The stock had previously closed at $14.71.

A number of research analysts have issued reports on CLVS shares. Piper Jaffray Cos. reiterated a “hold” rating and issued a $18.00 target price on shares of Clovis Oncology in a research report on Tuesday, April 5th. Leerink Swann lifted their target price on Clovis Oncology from $104.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, March 28th. Vetr upgraded Clovis Oncology from a “buy” rating to a “strong-buy” rating and set a $17.71 target price on the stock in a research report on Thursday, June 9th. Credit Suisse Group AG reiterated a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, June 8th. Finally, Mizuho reduced their price target on Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Monday, April 11th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of “Hold” and a consensus target price of $29.25.

The company has a 50-day moving average price of $14.76 and a 200-day moving average price of $18.14. The company’s market cap is $526.26 million.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.39) by $0.22. The company’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.86) EPS. On average, equities research analysts predict that Clovis Oncology Inc. will post ($8.00) EPS for the current year.

Several hedge funds have added to or reduced their stakes in CLVS. Rhumbline Advisers boosted its stake in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 1,880 shares during the last quarter. ProShare Advisors LLC boosted its stake in Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock valued at $1,265,000 after buying an additional 3,125 shares during the last quarter. California State Teachers Retirement System boosted its stake in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 889 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in Clovis Oncology during the fourth quarter valued at $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.